Menopause

Newly published data from a phase 3 study demonstrate the safety and efficacy of fezolinetant (Astellas) for treatment of VMS due to menopause.

At the International Society for the Study of Women’s Sexual Health conference, held March 2 through 5 in St. Louis, Missouri, Michael Krychman, digital editor for Contemporary OB/GYN® talked with Barb Dehn, NP, from El Camino Women’s Medical Group in Mountain View, California, about the importance of helping professional women cope with menopause.

A look at vaginal laser surgery for overactive bladder syndrome.

A new study suggests that ospemifene can reduce harmful bacteria and significantly contribute to vaginal health in postmenopausal women.

Investigators identify a strong association between exposure to air pollution and bone mineral loss in postmenopausal women.

Further adding to the discussion surrounding the impact of endocrine-disrupting chemicals, an analysis of data from the SWAN Multipollutant Study suggests increased exposure to phthlates was linked to a 30-63% increase in risk of developing diabetes among White women in midlife.

The US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for treatment of various conditions.

Research reveals that hormone therapy and alternative medicine do not enhance quality of life for midlife women experiencing menopause symptoms.

A recent study analyzed the effect artificially sweetened beverages have on urinary incontinence in women.

POLL: How do you compare with your colleagues in your comfort level for prescribing hormone replacement therapy for symptoms of menopause.

A new study in Menopause found body dissatisfaction to be a primary cause of eating disorders, especially during perimenopause.

If approved, DARE-HRT1 would become the first FDA-approved monthly intravaginal ring to deliver both estrogen and progestin hormone therapy.

Rebecca Thurston, PhD, sits down to discuss her research presented at the NAMS Annual Meeting on vasomotor symptoms and cardiovascular health.

For World Menopause Month, we revisit some of this year’s top menopause articles.

Rebecca Thurston, PhD, sits down to discuss the latest news from the North American Menopause Society Annual Meeting.

History of migraine may be associated with poor sleep in premenopausal and perimenopausal women, according to research presented at the North American Menopause Society Annual Meeting.

Traumatic experiences are associated with lower levels of sex hormones in midlife women, especially those with short sleep, according to research presented at the North American Menopause Society Annual Meeting.

A presentation at the North American Menopause Society Annual Meeting outlined the approval status and effectiveness of various pharmacologic treatments of vasomotor symptoms.

In a presentation at the North American Menopause Society Annual Meeting, a study found that women may be more inclined to gain weight during the menopause transition.

Women with diabetes are more susceptible to early menopause, according to a study presented at the North American Menopause Society Annual Meeting.

Hormone therapy was linked as a potential preventative treatment for adhesive capsulitis in menopausal women, according to a study presented at the North American Menopause Society Annual Meeting.

In a presentation at the North American Menopause Society Annual Meeting, investigators found these signs of menopause are 2 very separate symptoms and have different effects on stress and depression in menopausal women.

More women are using medical cannabis for menopause-related symptoms, according to research recently published in Menopause.

Women with shorter menstrual cycles may reach menopause earlier and experience more severe symptoms overall, according to research in Menopause.

Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).